Committee Connection
  • ASCO Names the Transformation of CLL Treatment as the Cancer Advance of the Year

    20 Jan 2015 09:48 AM

    The Clinical Cancer Advances 2015 report features the year’s top achievements, previews future trends   In just a year’s time, four therapies have been approved for patients with chronic lymphocytic leukemia (CLL). The new treatments are more effective and far easier to tolerate than prior therapies. This standout achievement, ASCO’s Advance of the Year, was announced as part of Clinical Cancer Advances 2015: ASCO’s Report on Progress... Read more

  • PQRS Reporting Available at a Discount through ASCO and CECity

    05 Jan 2015 11:24 AM

    ASCO has signed a contract with CECity to provide a substantial discount to eligible professionals (EP) who use CECity’s CMS-approved PQRSwizard registry to fulfill their 2014 reporting requirement. You can now access the PQRSwizard registry to begin meeting your reporting requirement before the February 26, 2015, deadline. CECity’s PQRSwizard registry includes all PQRS-approved measures and measure groups and will support multi-specialty practice... Read more

  • Molecular Oncology Tumor Boards

    18 Dec 2014 04:42 PM

    A new crowd-sourced learning tool from ASCO University As genetics and genomics become increasingly important in the treatment of cancer, the need for educational resources to help providers incorporate these new testing methodologies into practice has become vital. To help make this possible, ASCO University®, the College of American Pathologists, and the Association for Molecular Pathology have partnered to create the Molecular Oncology Tumor... Read more

  • ASCO Calls for New Action to Address Obesity and Cancer

    18 Dec 2014 10:48 AM

    ASCO has called for increased education, research, and advocacy to reduce the toll of obesity, both as a leading cause of cancer and a complication in the care of patients with cancer. With its first-ever policy statement on cancer and obesity, ASCO underscored that obesity is becoming a central challenge in cancer prevention and care, and is projected to overtake tobacco as the leading preventable cause of cancer in the United States.1The... Read more

  • Recently Released Clinical Practice Guidelines

    18 Dec 2014 10:38 AM

    Visit to read ASCO’s latest clinical guidance: Chemo- and Targeted Therapy for Women with HER2-Negative (or Unknown) Advanced Breast Cancer Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC) Molecular Testing for Selection of Patients with Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors... Read more

  • ASCO Issues New Template for Survivorship Care Plans

    18 Dec 2014 10:27 AM

    ASCO recently issued a new template for health care professionals to use when providing a survivorship care plan to patients who have completed curative cancer therapy. The survivorship care plan, updating a previous version ASCO developed nearly a decade ago, was published in the Journal of Oncology Practice (JOP) and contains important information about treatments the patient received, the need for future checkups and cancer tests,... Read more

  • New Website Launched for CancerLinQ, ASCO’s Rapid Learning System

    18 Dec 2014 10:19 AM

    ASCO’s Institute for Quality has developed a new interactive website for CancerLinQ™. Visit for the latest news and information from the Society about this cutting-edge health information technology platform that will revolutionize cancer care. Site features include new graphics to explain ASCO’s vision behind CancerLinQ, a timeline highlighting progress made and important moments throughout the system’s development, and more.... Read more

  • NCI Invites Clinicians to Identify Exceptional Responders

    17 Dec 2014 09:31 PM

    The National Cancer Institute (NCI) announced the launch of the Exceptional Responders Initiative, a study that will investigate the molecular factors associated with exceptional responses to treatment therapies. NCI plans to examine tissue and clinical data and conduct gene sequencing analysis on up to 300 cases.NCI is asking clinicians to identify possible exceptional responder cases to participate in the study. Patients are considered... Read more

  • FDA Posts Draft Guidance on Laboratory-Developed Tests

    17 Dec 2014 09:22 PM

    The U.S. Food and Drug Administration (FDA) published an online draft guidance proposing a risk-based phased-in framework for oversight of laboratory-developed tests (LDTs) that place patients at greater risk for harm if their results are not accurate. The FDA also published accompanying draft guidance that describes the notification process for LDTs and the Medical Device Reporting (MDR) requirements. The agency will be accepting... Read more

  • January 2015 Highlights from the Exclusive Coverage Series

    14 Dec 2014 05:56 PM

    Featuring interviews with authors of recent JCO and JOP Original Reports“Exclusive Coverage” is a series of articles on designed to provide quick insight and additional author perspectives on select studies recently published in the Journal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP). Based on interviews conducted with the lead or corresponding researchers behind Original Reports, Exclusive Coverage... Read more